Table 2 Cox proportional hazard regression analyses for 5-year survival.
From: RALYL increases hepatocellular carcinoma stemness by sustaining the mRNA stability of TGF-β2
Clinicopathological features | Multivariate analysis | Un-variate analysis | ||||
|---|---|---|---|---|---|---|
HR | 95% CI | P value | HR | 95% CI | P value | |
Age | ||||||
<60 years vs. >60 years | 0.487 | 0.316–1.728 | 0.485 | 0.079 | 0.444–2.960 | 0.778 |
Gender | ||||||
Male vs. female | 0.239 | 0.220–2.483 | 0.625 | 0.264 | 0.268–2.159 | 0.607 |
TNM stage | ||||||
I vs. II and III | 0.434 | 0.281–1.879 | 0.510 | 11.751 | 0.158–0.605 | 0.001 |
Tumor size | ||||||
≤5 cm vs. >5 cm | 0.985 | 0.718–2.753 | 0.321 | 0.659 | 0.379–1.495 | 0.417 |
Differentiation | ||||||
Poor vs. well | 4.579 | 0.192–0.930 | 0.032 | 7.244 | 0.164–0.752 | 0.007 |
Cirrhosis | ||||||
Absent vs. present | 0.322 | 0.282–2.009 | 0.570 | 2.579 | 0.852–4.993 | 0.108 |
Vascular invasion | ||||||
Absent vs. present | 3.283 | 0.115–1.089 | 0.070 | 21.503 | 0.291–13.916 | <0.001 |
RALYL expression | ||||||
Absent vs. present | 3.936 | 0.245–0.992 | 0.047 | 4.204 | 0.344–0.969 | 0.040 |
CD133 upregulation | ||||||
No vs. yes | 4.670 | 0.218–0.928 | 0.031 | 5.057 | 0.236–0.906 | 0.025 |
TGF-β2 upregulation | ||||||
No vs. yes | 0.369 | 0.347–1.746 | 0.543 | 9.186 | 0.183–0.695 | 0.002 |
